FrancophonIA/ELRC3.0 huggingface dataset:
English: In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNF, there was no indication of maternal toxicity, embryotoxicity or teratogenicity (see section 5.3).
Maltese: Fi studju dwar it-tossiċità fuq l-iżvilupp li sar fuq ġrieden bl-użu ta' antikorp analogu li b'mod selettiv jimpedixxi l-attività funzjonali ta' TNF tal-ġrieden, ma kienx hemm indikazzjoni ta' tossiċità għall-omm, tossiċità għall-embriju jew tertoġeniċità (ara sezzjoni 5.3).
English: There is limited safety experience of Remicade treatment in patients who have undergone surgical procedures, including arthroplasty.
Maltese: Hemm esperjenza limitata dwar is-sigurtà tal-kura b'Remicade f'pazjenti li kellhom proċeduri kirurġiċi, inkluż arthroplasty f'pazjenti kkurati b'Remicade.
English: • Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating.
Maltese: • Sinjali ta' infezzjoni (inkluża TB) bħal deni, tħossok għajjien, sogħla li tista' tkun persistenti, qtugħ ta' nifs, sintomi bħal tal-influwenza, telf tal-piż, issir għarqan/a bil-lejl, dijarea, ġrieħi, tinġabar il-materja fl-intern jew madwar l-anus (axxess), problemi fis-snien jew tħoss ħruq meta tgħaddi l-awrina.
English: Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF but not to lymphotoxin  (TNFß).
Maltese: Jekk issir dijanjosi ta' tuberkulożi mhux attiva (‘moħbija') terapija kontra t-tuberkulożi moħbija għandha tinbeda b'terapija kontra t-tuberkulożi qabel ma' jinbeda Remicade, u skont irrakkomandazzjonijiet lokali.
English: At week 12, placebo patients were switched to infliximab 5 mg/kg every 6 weeks up to week 54.
Maltese: F'ġimgħa 12, pazjenti fuq plaċebo inqalbu fuq infliximab 5 mg/kg kull 6 ġimgħat sa ġimgħa 54.
English: If response was lost during maintenance treatment, crossing over to a higher dose (10 mg/kg) and/or shorter dosing interval (q8 weeks) was allowed.
Maltese: Jekk ir-rispons intilef waqt il-kura ta' manteniment, kien permess li jinqalbu fuq doża ogħla (10 mg/kg) u/jew li jkollhom intervall ta' għoti tad-doża iqsar (q8 ġimgħat).
English: If you have active psoriatic arthritis you will first be given other medicines.
Maltese: Jekk għandek artrite bi psorjasi attiva l-ewwel se tingħata mediċini oħra.
English: • in combination with methotrexate
Maltese: .8 Effetti mhux mixtieqa
English: Discontinuation of Remicade therapy should be considered in patients with confirmed significant haematologic abnormalities.
Maltese: KONDIZZJONIJIET JEW RESTRIZZJONIJIET FIRRIGWARD TAL-UŻU SIGUR U EFFETTIV TAL-PRODOTT MEDIĊINALI
English: In a 6-month repeated dose toxicity study in mice, using the same analogous antibody against mouse TNF, crystalline deposits were observed on the lens capsule of some of the treated male mice.
Maltese: Fi studju li dam 6 xhur dwar tossiċità b'dożi ripetuti li sar fil-ġrieden, fejn intuża l-istess antikorp analogu kontra TNF tal-ġrieden, depożiti kristallini kienu osservati fuq il-kapsula tal-lenti ta' wħud mil-ġrieden irġiel ikkurati.
English: Telephone number doctor:
Maltese: Għoti ta' mediċini kurrenti:
English: • Tell your doctor straight away if you have signs of an infection.
Maltese: • Għid lit-tabib tiegħek immedjatament jekk għandek sinjali ta' infezzjoni.
English: Common: Conjunctivitis.
Maltese: Komuni ħafna:
English: België/Belgique/Belgien MSD Belgium BVBA/SPRL Tél/Tel: +32(0)27766211 dpoc_belux@merck.com
Maltese: België/Belgique/Belgien MSD Belgium BVBA/SPRL Tél/Tel:
English: Further information on Deferasirox Mylan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/deferasirox-mylan.
Maltese: Aktar informazzjoni dwar Deferasirox Mylan tista' tinstab fis-sit web tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/deferasirox-mylan.
English: Deferasirox Mylan (deferasirox)
Maltese: Deferasirox Mylan (deferasiroks)
English: Deferasirox Mylan is available as film-coated tablets (90 mg, 180 mg and 360 mg), to be taken once a day at around the same time.
Maltese: Deferasirox Mylan jiġi bħala pilloli miksijin b'rita (90 mg, 180 mg u 360 mg), li għandhom jittieħed darba kuljum bejn wieħed u ieħor fl-istess ħin.
English: Deferasirox Mylan contains the active substance deferasirox and is a ‘generic medicine'.
Maltese: Deferasirox Mylan fih is-sustanza attiva deferasiroks u huwa ‘mediċina ġenerika'.
English: Other information about Deferasirox Mylan
Maltese: Informazzjoni oħra dwar Deferasirox Mylan
English: • patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin - the protein that carries oxygen around the body - in the blood) and who receive frequent blood transfusions;
Maltese: • f'pazjenti minn sitt snin 'il fuq li jbatu mill-beta talassemija maġġuri (disturb ereditarju fid-demm fejn il-pazjenti ma jkollhomx emoglobina normali biżżejjed - il-proteina li ġġorr l-ossiġnu madwar il-ġisem - fid-demm) u li jingħataw trasfużjonijiet tad-demm b'mod frekwenti;
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Exjade, and do not need to be repeated for Deferasirox Mylan.
Maltese: Diġà saru studji dwar il-benefiċċji u r-riskji tas-sustanza attiva fl-użijiet awtorizzati bil-mediċina ta' referenza, Exjade, u ma għandhomx għalfejn jiġu ripetuti għal Deferasirox Mylan.
English: Because Deferasirox Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Deferasirox Mylan huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: As for all medicines, data on the use of Deferasirox Mylan are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Deferasirox Mylan hija ssorveljata kontinwament.
English: What are the benefits and risks of Deferasirox Mylan?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Deferasirox Mylan?
English: Non-transfusion-dependent thalassaemia syndromes are blood disorders similar to beta thalassaemia major but which do not require blood transfusions.
Maltese: Is-sindromi tattalassemija li mhumiex dipendenti mit-trasfużjonijiet huma disturbi fid-demm simili għall-beta talassemija maġġuri iżda li ma jeħtiġux trasfużjonijiet tad-demm.
English: Side effects reported with Deferasirox Mylan are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Deferasirox Mylan huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex il-pazjenti jiġu protetti.
English: • children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate;
Maltese: • fi tfal bejn is-sentejn u l-ħames snin li jbatu mill-beta talassemija maġġuri li jingħataw trasfużjonijiet tad-demm b'mod frekwenti, meta deferoxamine (mediċina oħra użata fil-kura talammont eċċessiv ta' ħadid) ma tkunx tista' tintuża jew ma tkunx adegwata;
English: The European Medicines Agency concluded that, in accordance with EU requirements, Deferasirox Mylan has been shown to have comparable quality and to be bioequivalent to Exjade.
Maltese: L-Aġenzija Ewropea għall-Mediċini kkonkludiet li, b'mod konformi mar-rekwiżiti tal-UE, Deferasirox Mylan wera li għandu kwalità komparabbli u huwa bijoekwivalenti għal Exjade.
English: How has Deferasirox Mylan been studied?
Maltese: Kif ġie studjat Deferasirox Mylan?
English: This pack aims to inform them about the treatment recommendations with Deferasirox Mylan, including choosing the right dose and the need to monitor the patient's health, especially kidney function.
Maltese: Dan il-pakkett għandu l-għan li jinformahom dwar irrakkomandazzjonijiet ta' kura b'Deferasirox Mylan, inkluż l-għażla tad-doża ġusta u l-bżonn li tkun issorveljata s-saħħa tal-pazjent, speċjalment il-funzjoni tal-kliewi.
English: What measures are being taken to ensure the safe and effective use of Deferasirox Mylan?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Deferasirox Mylan?
English: • patients from 2 years of age who suffer from other types of anaemia (low levels of haemoglobin in the blood) and who receive blood transfusions, when deferoxamine cannot be used or is inadequate;
Maltese: • f'pazjenti minn sentejn 'il fuq li jbatu minn tipi oħra ta' anemija (livelli baxxi ta' emoglobina fiddemm) u li jingħataw trasfużjonijiet tad-demm, meta deferoxamine ma tkunx tista' tintuża jew ma tkunx adegwata;
English: As for every medicine, the company provided studies on the quality of Deferasirox Mylan.
Maltese: Bħal fil-każ ta' kull mediċina, il-kumpanija pprovdiet studji dwar il-kwalità ta' Deferasirox Mylan.
English: The company that markets Deferasirox Mylan must issue an education pack to healthcare professionals.
Maltese: Il-kumpanija li tqiegħed Deferasirox Mylan fis-suq għandha toħroġ pakkett edukattiv għallprofessjonisti fil-qasam tal-kura tas-saħħa.
English: The active substance in Deferasirox Mylan, deferasirox, is an ‘iron chelator'.
Maltese: Issustanza attiva f'Deferasirox Mylan, id-deferasiroks, hija ‘kelatur tal-ħadid'.
English: Trydonis (beclometasone / formoterol / glycopyrronium bromide)
Maltese: Trydonis (beklometażona / formoterol / glikopirronju bromur)
English: Trydonis received a marketing authorisation valid throughout the EU on 26 April 2018.
Maltese: Trydonis ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fis-26 ta' April 2018.
English: Further information on Trydonis can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis.
Maltese: Aktar informazzjoni dwar Trydonis tinstab fis-sit elettroniku tal-Aġenzija: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis.
English: Other information about Trydonis
Maltese: Informazzjoni oħra dwar Trydonis
English: Trydonis is available as a liquid in a portable inhaler device.
Maltese: Trydonis jiġi bħala likwidu f'apparat inalatur portabbli.
English: Trydonis contains the active substances beclometasone, formoterol and glycopyrronium bromide.
Maltese: Trydonis fih is-sustanzi attivi l-beklometażona, il-formoterol u l-glikopirronju bromur.
English: Side effects with Trydonis include oral candidiasis (a fungal infection of the mouth caused by a yeast called Candida), muscle spasms and dry mouth.
Maltese: L-effetti sekondarji bi Trydonis jinkludu kandidjażi orali (infezzjoni fungali tal-ħalq ikkawżata minn ħmira msejħa Candida), spażmi tal-muskoli u ħalq xott.
English: By comparison, the FEV1 increased by 1 and 145 ml before and after dosing in patients treated with a medicine containing only 2 of the active substances found in Trydonis (beclometasone plus formoterol).
Maltese: B'paragun, l-FEV1 żdied b'1 u b'145 ml qabel u wara d-doża rispettivament f'pazjenti kkurati b'mediċina li fiha biss tnejn miż-żewġ sustanzi attivi li jinsabu fi Trydonis (il-beklometażona flimkien ma' formoterol).
English: In the first study lasting a year, after 26 weeks of treatment, Trydonis improved patients' FEV1 (the maximum volume of air a person can breathe out in one second) by 82 ml before a dose and 261 ml after a dose.
Maltese: Fl-ewwel studju li dam sena, wara 26 ġimgħa ta' kura, Trydonis tejjeb l-FEV1 (il-volum massimu ta' arja li persuna tista' toħroġ man-nifs f'sekonda) tal-pazjenti bi 82 ml qabel doża u b'261 ml wara doża.
English: In the third study lasting a year, patients treated with Trydonis had 15% fewer exacerbations a year than patients treated with a combination of indacaterol (a long-acting beta-2 agonist) and glycopyrronium bromide.
Maltese: Fit-tielet studju li dam sena, il-pazjenti kkurati bi Trydonis kellhom 15 % taħrix inqas fis-sena minn pazjenti kkurati b'kombinazzjoni ta' indakaterol (agonista ta' beta-2 li taħdem fit-tul) u l-glikopirronju bromur.
English: Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs..
Maltese: Agonisti ta' beta-2 u antagonisti ta' riċettur muskariniku jgħinu biex il-passaġġi tal-arja jitwessgħu; kortikosterojdi jnaqqsu l-infjammazzjoni fil-passaġġi tal-arja u filpulmuni.
English: Trydonis is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist.
Maltese: Trydonis jintuża għal kura ta' manteniment (regolari) f'pazjenti li l-marda tagħhom ma tkunx ikkontrollata b'mod adegwat minkejja kura b'kombinazzjoni ta' żewġ mediċini COPD li jikkonsistu minn agonista ta' beta-2 li taħdem fit-tul flimkien ma' jew kortikosterojde inalata jew ma' antagonista ta' riċettur muskariniku li taħdem fit-tul.
English: The company that makes Trimbow has agreed that its scientific data can be used for Trydonis (‘informed consent').
Maltese: Il-kumpanija li tipproduċi Trimbow qablet li d-data xjentifika tiegħu tista' tintuża għal Trydonis (“kunsens infurmat”).
English: Trydonis has been shown to be effective at relieving symptoms of COPD in three main studies involving over 5,500 patients whose symptoms were not controlled well enough either by combinations of two other COPD medicines or by a muscarinic receptor antagonist alone.
Maltese: Trydonis intwera li hu effettiv biex itaffi s-sintomi ta' COPD fi tliet studji ewlenin li kienu jinvolvu iktar minn 5 500 pazjent li s-sintomi tagħhom ma kinux ikkontrollati tajjeb biżżejjed minn l-ebda waħda mill-kombinazzjonijiet ta' żewġ mediċini COPD oħrajn jew minn antagonista ta' riċettur muskariniku waħdu.
English: How is Trydonis used?
Maltese: Kif jintuża Trydonis?
English: In the second study lasting a year, patients treated with Trydonis had 20% fewer exacerbations (flareups of symptoms) per year than patients treated with tiotropium (a long-acting muscarinic receptor antagonist).
Maltese: Fit-tieni studju li dam sena, il-pazjenti kkurati bi Trydonis kellhom 20 % taħrix inqas (attakki mill-ġdid tas-sintomi) fis-sena minn pazjenti kkurati b'tiotropju (antagonista tar-riċettur muskariniku li taħdem fit-tul).
English: As for all medicines, data on the use of Trydonis is continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Trydonis hija ssorveljata kontinwament.
English: In this study, Trydonis was as effective as tiotropium plus a combination of beclometasone and formoterol at reducing the number of exacerbations.
Maltese: F'dan l-istudju, Trydonis kien effettiv daqs tiotropju flimkien ma' kombinazzjoni ta' beklometażona u formoterol biex inaqqas in-numru ta' taħrix.
English: What are the risks associated with Trydonis?
Maltese: X'inhuma r-riskji assoċjati ma' Trydonis?
English: No major safety concerns have been reported with Trydonis, with side effects being manageable and similar to other COPD medicines.
Maltese: Ma ġie rrappurtat l-ebda tħassib maġġuri dwar is-sigurtà bi Trydonis, bl-effetti sekondarji li jistgħu jiġu mmaniġġjati u li huma simili għal mediċini oħra tas-COPD.
English: Because these receptors help control the contraction of the airway muscles, blocking them causes the muscles to relax, helping to keep the airways open and allowing the patient to breathe more easily.
Maltese: L-effetti sekondarji rrappurtati bi Trydonis huma evalwati bir-reqqa u tittieħed kull azzjoni meħtieġa biex tipproteġi lill-pazjenti.
English: The infusion should last 30 minutes.
Maltese: L-infużjoni għandha ddum 30 minuta.
English: Fasturtec rasburicase
Maltese: Fasturtec rasburikaże
English: The full EPAR for Fasturtec can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ għal Fasturtec jinsab fis-sit tal-Aġenzija : ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Fasturtec is a medicine that contains the active substance rasburicase.
Maltese: Fasturtec huwa mediċina li fiha s-sustanza attiva rasburikaże.
English: Other information about Fasturtec
Maltese: Informazzjoni oħra dwar Fasturtec
English: This is a summary of the European public assessment report (EPAR) for Fasturtec.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Fasturtec.
English: The benefits of Fasturtec were first studied in three main studies involving a total of 293 patients, including adults and children.
Maltese: Il-benefiċċji ta' Fasturtec ġew studjati fi tliet studji ewlenin li kienu jinvolvu total ta' 293 pazjent, inklużi adulti u tfal.
English: The enzyme was originally extracted from a fungus, but in Fasturtec it is produced by a method known as ‘recombinant DNA technology': it is made by a yeast into which a gene (DNA) has been introduced that makes it able to produce urate oxidase.
Maltese: Oriġinarjament l-enzima kienet estratta minn fungu, iżda f'Fasturtec tiġi prodotta b'metodu magħruf bħala ‘teknoloġija rikombinanti tad-DNA': tiġi magħmula minn ħmira li tkun irċeviet ġene (DNA) li tagħmilha kapaċi tipproduċi l-urat ossidażi.
English: In the comparative study, Fasturtec was more effective than allopurinol: over the first 96 hours after treatment, patients treated with Fasturtec had a lower average blood level of uric acid than the patients treated with allopurinol (128.1 and 328.5 mg.h/dl, respectively).
Maltese: Fl-istudju tat-tqabbil, Fasturtec kien iktar effikaċi minn allopurinol: matul l-ewwel 96 siegħa wara l-kura, il-pazjenti kkurati b'Fasturtec kellhom medja iktar baxxa ta' livell ta' aċidu uriku fid-demm mill-pazjenti kkurati b'allopurinol (128.1 u 328.5 mg.h/dl, rispettivament).
English: What is Fasturtec?
Maltese: X'inhu Fasturtec?
English: Fasturtec must not be used in patients with a deficiency in (low levels of) glucose 6 phosphate dehydrogenase (G6PD) or other metabolic disorders known to cause haemolytic anaemia (low haemoglobin levels caused by the abnormal breakdown of red blood cells).
Maltese: Fasturtec m'għandux jintuża f'pazjenti b'defiċjenza (livelli baxxi) ta' glukożju-6-fosfat deidroġenażi (G6PD) jew disturbi metaboliċi oħra magħrufa li jikkawżaw anemija emolitika (livelli baxxi ta' emoglobini kkawżati mit-tkissir anomalu taċ-ċelloli ħomor tad-demm).
English: The active substance in Fasturtec, rasburicase, is an enzyme called urate oxidase, which transforms uric acid into another chemical called allantoin, which can easily be excreted by the kidneys in the urine.
Maltese: Is-sustanza attiva f'Fasturtec, ir-rasburikaże, hija enzima msejħa urat ossidażi, li tittrasforma l-aċidu uriku f'kimika oħra msejħa allantoina li tista' tiġi estratta faċilment mill-kliewi fl-awrina.
English: The recommended dose is 0.2 mg per kilogram body weight in both children and adults, given as a daily infusion for up to seven days.
Maltese: Id-doża rakkomandata hija 0.2 mg kull kilogramm ta' piż tal-ġisem kemm fit-tfal kif ukoll fl-adulti, li tingħata bħala infużjoni kuljum sa sebat ijiem.
English: An additional study looked at the effects of Fasturtec in 21 children (aged between 6 months and 16 years) with blood cancers of whom 62% had uric acid levels that were too high.
Maltese: Studju addizzjonali ffoka fuq l-effetti ta' Fasturtec f'21 tifel u tifla (li kellhom etajiet ivarjaw bejn 6 xhur u 16-il sena) li kienu jbatu b'kanċers fid-demm li minnhom 62% kellhom il-livelli ta' aċidu uriku wisq għoljin.
English: How has Fasturtec been studied?
Maltese: Kif ġie studjat Fasturtec?
English: The most common side effects with Fasturtec (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, headache, fever and diarrhoea.
Maltese: L-effetti sekondarji l-aktar komuni b'Fasturtec (li dehru f'aktar minn pazjent wieħed minn 10) huma nawżja (tħosok ma tiflaħx), remettar, uġigħ ta' ras, deni u dijarea.
English: The dose-finding studies showed that, after 48 hours, Fasturtec at a daily dose of 0.2 mg per kg reduced the uric acid levels to normal in 95% of patients.
Maltese: L-istudji għas-sejbien tad-doża wrew li, wara 48 siegħa, Fasturtec f'doża ta' kuljum ta' 0.20 mg/kg naqqas il-livelli ta' aċidu uriku għan-normal f'95% tal-pazjenti.
English: Fasturtec was only compared with another treatment (allopurinol, the standard treatment for reducing uric acid levels) in one of the studies, which included 52 patients.
Maltese: Fasturec tqabbel biss ma' kura oħra (allopurinol, il-kura standard għat-tnaqqis tal-livelli tal-aċidu uriku) f'wieħed mill-istudji, li fih ħadu sehem 52 pazjent.
English: What is the risk associated with Fasturtec?
Maltese: X'inhu r-riskju assoċjat ma' Fasturtec?
English: Why has Fasturtec been approved?
Maltese: Għaliex ġie approvat Fasturtec?
English: It is available as a powder and solvent that are made up into a solution for infusion (drip) into a vein.
Maltese: Jiġi bħala trab u solvent li jitħalltu biex isiru soluzzjoni għal infużjoni (dripp) fil-vina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Fasturtec on 23 February 2001.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Fasturtec fit-23 ta' Frar 2001.
English: Fasturtec was not compared with another medicine in this study.
Maltese: Fasturtec ma tqabbilx ma mediċina oħra f'dan l-istudju.
English: In the additional study, none of the 21 children treated with Fasturtec had high uric acid levels after 24 or 48 hours.
Maltese: Fl-istudju addizzjonali, l-ebda wieħed mill-21 tifel u tifla kkurati b'Fasturtec ma kellhom livelli għolja ta' aċidu uriku wara 24 jew 48 siegħa.
English: It is used in adults and children with blood cancers who are at risk of a sudden rise in uric acid levels when they start to receive chemotherapy (medicines to treat cancer).
Maltese: Jintuża fl-adulti u t-tfal li jbatu minn kanċers fid-demm u li qegħdin f'riskju ta' żieda għall-għarrieda tal-livelli tal-aċidu uriku meta jibdew jirċievu l-kimoterapija (mediċina għall-kura tal-kanċer).
English: 1adjuvanted by AS04C containing: - 3-O-desacyl-4'- monophosphoryl lipid A (MPL) 2
Maltese: 1aġġuvinat b'AS04C li fih: - 3-O-desacyl-4'- monophosphoryl lipid A (MPL)
English: 2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total) 3produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
Maltese: 2adsorbit fuq aluminium phosphate (0.5 milligramma Al3+ b'kollox) 3prodott f'ċelloli tal-ħmira (Saccharomyces cerevisiae) b'teknoloġija rikombinanti tad-DNA
English: 1 dose (0.5 ml) contains: Hepatitis B surface antigen 1, 2, 3
Maltese: 1 doża (0.5 ml) fiha: Antiġen tal-wiċċ tal-epatite B 1, 2, 3
English: 1 pre-filled syringe + 1 needle
Maltese: 1 siringa mimlija għal-lest + 1 labra
English: MA (EU) number (Invented) name Strength Pharmaceutical form
Maltese: Numri tal-MA (UE)
English: Filters at 15 nm, 30 nm, 50 nm and 80 nm filter pore size were used.
Maltese: Filtri f'15 nm, 30 nm, 50 nm u daqs tal-pori talfiltri ta' 80 nm intużaw.
English: Applicant
Maltese: Leidenius
English: Chakera et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
Maltese: EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
English: 1 Buscombe et al. Sentinel node in breast cancer procedural guidelines.
Maltese: Sentinel node in breast cancer procedural guidelines.
English: • The Committee considered the notification of the referral triggered by the Germany under Article 29(4) of Directive 2001/83/EC;
Maltese: • Il-Kumitat ikkunsidra n-notifika tar-riferiment mibdija mill-Ġermanja skont l-Artikolu 29(4) tadDirettiva 2001/83/KE;
English: 4 Leidenius MH, et al.
Maltese: MH, et al.